26.60 USD
▼+0.03-1.00%
2026-08-03
市值
$111.73M
市盈率
—
EPS
-5.22
股息率
—
52 周区间
4.97 – 45.50
成交量
187.72K
Beta
2.46
目标价
—
52W 低 4.9752W 高 45.50
价格走势
公司简介
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company’s lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company’s lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inf...